Valerius T - Search Results

1

Enhanced killing of B lymphoma cells by granulocyte colony-stimulating factor-primed effector cells and Hu1D10--a humanized human leucocyte antigen DR antibody.

Stockmeyer B, Schiller M, Repp R, Lorenz HM, Kalden JR, Gramatzki M, Valerius T. Stockmeyer B, et al. Among authors: valerius t. Br J Haematol. 2002 Sep;118(4):959-67. doi: 10.1046/j.1365-2141.2002.03722.x. Br J Haematol. 2002. PMID: 12199773 Free article.

2

Effects of IFN on human eosinophils in comparison with other cytokines. A novel class of eosinophil activators with delayed onset of action.

Valerius T, Repp R, Kalden JR, Platzer E. Valerius T, et al. J Immunol. 1990 Nov 1;145(9):2950-8. J Immunol. 1990. PMID: 1698867

3

Neutrophils express the high affinity receptor for IgG (Fc gamma RI, CD64) after in vivo application of recombinant human granulocyte colony-stimulating factor.

Repp R, Valerius T, Sendler A, Gramatzki M, Iro H, Kalden JR, Platzer E. Repp R, et al. Among authors: valerius t. Blood. 1991 Aug 15;78(4):885-9. Blood. 1991. PMID: 1714327 Free article.

4

Involvement of the high-affinity receptor for IgG (Fc gamma RI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy.

Valerius T, Repp R, de Wit TP, Berthold S, Platzer E, Kalden JR, Gramatzki M, van de Winkel JG. Valerius T, et al. Blood. 1993 Aug 1;82(3):931-9. Blood. 1993. PMID: 7687898 Free article.

5

In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects.

Lorenz HM, Antoni C, Valerius T, Repp R, Grünke M, Schwerdtner N, Nüsslein H, Woody J, Kalden JR, Manger B. Lorenz HM, et al. Among authors: valerius t. J Immunol. 1996 Feb 15;156(4):1646-53. J Immunol. 1996. PMID: 8568271 Clinical Trial.

6

G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210).

Repp R, Valerius T, Wieland G, Becker W, Steininger H, Deo Y, Helm G, Gramatzki M, Van de Winkel JG, Lang N, et al. Repp R, et al. Among authors: valerius t. J Hematother. 1995 Oct;4(5):415-21. doi: 10.1089/scd.1.1995.4.415. J Hematother. 1995. PMID: 8581378 Review.

7

HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor.

Elsässer D, Valerius T, Repp R, Weiner GJ, Deo Y, Kalden JR, van de Winkel JG, Stevenson GT, Glennie MJ, Gramatzki M. Elsässer D, et al. Among authors: valerius t. Blood. 1996 May 1;87(9):3803-12. Blood. 1996. PMID: 8611706 Free article.

8

Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer.

Stockmeyer B, Valerius T, Repp R, Heijnen IA, Bühring HJ, Deo YM, Kalden JR, Gramatzki M, van de Winkel JG. Stockmeyer B, et al. Among authors: valerius t. Cancer Res. 1997 Feb 15;57(4):696-701. Cancer Res. 1997. PMID: 9044847

9

HLA class II antibodies recruit G-CSF activated neutrophils for treatment of B cell malignancies.

Valerius T, Elsässer D, Repp R, Van de Winkel JG, Gramatzki M, Glennie M. Valerius T, et al. Leuk Lymphoma. 1997 Jul;26(3-4):261-9. doi: 10.3109/10428199709051775. Leuk Lymphoma. 1997. PMID: 9322888 Review.

10

FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy.

Valerius T, Stockmeyer B, van Spriel AB, Graziano RF, van den Herik-Oudijk IE, Repp R, Deo YM, Lund J, Kalden JR, Gramatzki M, van de Winkel JG. Valerius T, et al. Blood. 1997 Dec 1;90(11):4485-92. Blood. 1997. PMID: 9373259 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

179 results

Search Page

Filters